Epidemiology & Pathophysiology Overview

Pericarditis accounts for ~5% of non–ST-elevation chest pain presentations in emergency departments. Acute pericarditis affects 1–3 cases per 1,000 person-years, with peak incidence in young to middle-aged adults (mean age 45–55 years). Idiopathic/viral etiology accounts for ~80% of primary acute cases; post-cardiac injury syndromes (e.g., post-MI, post-pericardiotomy) represent another 10%; autoimmune, neoplastic, metabolic (e.g., uremia), and infectious (bacterial, tuberculous, fungal) causes constitute the remainder.

The pericardium is rich in pain-sensitive nerve endings (especially parietal layer innervated by phrenic and intercostal nerves), explaining the characteristic positional chest pain. Inflammation leads to increased capillary permeability, fibrin deposition, and fluid accumulation—potentially progressing to effusion or tamponade.

Recurrence occurs in 15–30% of cases, with higher rates (up to 40%) after first recurrence and up to 80% in those failing initial colchicine therapy. Risk factors for recurrence include: young age, female sex, large effusion at presentation, absence of myocardial involvement, autoimmune comorbidities, and suboptimal initial colchicine dosing/duration.

Diagnostic Evaluation: Key Clinical & Diagnostic Criteria

I. Clinical Presentation

• Chest Pain: Sharp, pleuritic, retrosternal or left precordial; exacerbated by deep inspiration, coughing, supination, or recumbency; relieved by sitting upright and leaning forward.
• Associated symptoms: Dyspnea (often positional), dry cough, low-grade fever, malaise.
• Red flags suggesting alternative diagnosis:
  • Pain radiating to back/neck (aortic dissection)
  • Pressure/weight sensation (STEMI/NSTEMI)
  • Pericardial friction rub absent in ~25% of cases—especially with large effusions or delayed presentation.

II. Diagnostic Workup: Evidence-Based Recommendations

Per ESC 2015 guidelines and updated AHA/ACC/HRS 2023 scientific statement recommend a structured approach to diagnosis.

III. Advanced Imaging (When Indicated)

• Cardiac MRI:
  • Indications: Suspected myocardial involvement, diagnostic uncertainty, recurrent disease unresponsive to therapy.
  • Findings: Pericardial late gadolinium enhancement (LGE), thickened enhancing pericardium (>3–4 mm), T2 hyperintensity, effusion. Sensitivity ~85%, specificity >90% for active inflammation.
• Pericardial Fluid Analysis (if tapping):
  • Purulent: Neutrophil predominance, low glucose, positive cultures—requires urgent drainage + antibiotics.
  • TB suspect: Lymphocyte-predominant ADA >40 U/L or PCR+; treat empirically while awaiting results.
  • Malignancy: Elevated LDH, protein >3 g/dL, cytology+, CD15+/calretinin+.

Management of Acute Pericarditis

I. First-Line Therapy: NSAIDs + Colchicine (ESC/AHA/ACC/HRS Class I Recommendation)

• NSAID regimen:
  • Ibuprofen: 600–800 mg PO TDS for 1–2 weeks, taper over 1–2 weeks. Avoid if eGFR <30 mL/min or GI bleed risk.
  • Aspirin: 750–1,000 mg TDS for 1–2 weeks; preferred in known CAD (COX-2 sparing, antiplatelet effect). Taper by 250–500 mg every 1–2 weeks. Total dose ≤4 g/day.
  • Avoid NSAIDs in uremia, CKD stage 4/5, heart failure with reduced EF <40%, or recent GI bleed.
• Colchicine adjunct (dosing per ICOPA and CAPIRE trials):
  • Weight-based:
    • ≥70 kg: 0.6 mg BID × 3 months
    • <70 kg: 0.5 mg daily × 3 months
  • Monitoring: CBC, LFTs; watch for diarrhea (dose-limiting); avoid in severe CKD (eGFR <30 mL/min) without dose adjustment.
  • Mechanism: Inhibits microtubule assembly → suppresses NLRP3 inflammasome → reduces IL-1β/IL-18 release.

Evidence: Meta-analysis (Lancet 2022; n=9 RCTs, n=746) shows colchicine + NSAID reduces recurrence at 18 months by 56% vs NSAID alone (RR 0.44; 95% CI 0.32–0.60), with NNT = 4.

II. Second-Line & Rescue Therapies

• Corticosteroids: Class III recommendation for routine use in acute pericarditis (increases recurrence risk 2–4-fold).
  • Exceptions (conditional recommendation):
    • Contraindications/intolerance to NSAIDs/colchicine
    • Underlying autoimmune disease (e.g., SLE, vasculitis)
    • Uremic pericarditis
    • Post-pericardiotomy syndrome refractory to standard therapy
  • Dosing: Prednisone 0.2–0.5 mg/kg/day (max 30–40 mg) for 1–2 weeks, then rapid taper over ≤2 weeks—avoid prolonged courses.
• Pericardiocentesis/Drainage:
  • Indicated: Cardiac tamponade (Class I), suspected pyogenic infection (Class I).
  • Consider: Large effusion (>2 cm diastolic separation) with hemodynamic compromise, or diagnostic uncertainty.
  • Catheter drainage preferred over single-shot tap to prevent reaccumulation.
• Exercise Restriction:
  • Athletes: Minimum 3 months off competitive sports, guided by CRP normalization, ECG improvement (ST/T resolution), and absence of effusion on echo (ESC Sports Cardiology Consensus 2020).
  • Non-athletes: Avoid heavy lifting/Valsalva until symptom-free + CRP normal.
• Hospitalization Indications:
  • Fever >38°C, subacute onset + large effusion, immunosuppression, anticoagulation, elevated troponin + ST depression in aVR (suggests early STEMI mimic), or inability to follow up rapidly.

Management of Recurrent Pericarditis

I. First-Line: NSAID + Colchicine (Prolonged Course)

• NSAID: Maximal tolerated dose until symptom-free × 1–2 weeks, then taper slowly over weeks to months.
• Colchicine:
  • 0.5–0.6 mg BID for ≥6 months (minimum), up to 12 months in refractory cases (per REPER and STAPRA trials).
  • Consider once-daily extended-release colchicine 0.5 mg daily if GI intolerance.

II. Second-Line: IL-1 Inhibition

• Rilonacept (Arcalyst®):
  • Indication: Recurrent pericarditis ≥2 episodes despite NSAID + colchicine (Class I, ESC 2023 update).
  • Dosing:
    • Loading: 320 mg SC (two 160-mg injections at separate sites) on Day 1
    • Maintenance: 160 mg SC weekly
  • Efficacy: In the IL-1 Pericarditis Trial (N Engl J Med 2020), rilonacept reduced recurrence risk by 94% vs placebo at 12 months (HR 0.06; p<0.001).
  • Monitoring: CBC, LFTs, CRP weekly initially; watch for injection-site reactions and upper respiratory infections.
• Anakinra (off-label):
  • Daily SC 100 mg; faster onset (days) but shorter half-life.
  • Preferred if rapid control needed (e.g., status post tamponade).

III. Third-Line Options

• IVIG (500–1,000 mg/kg/day × 2–5 days): Case reports/series show efficacy in steroid-dependent patients; mechanism unclear (modulates cytokines/autoantibodies).
• Azathioprine (2–3 mg/kg/day): Adjunct to reduce steroid burden; monitor TPMT activity and CBC.
• Methotrexate (15–25 mg weekly): Consider in autoimmune overlap syndromes.

Corticosteroid Use in Recurrence

• Avoid empiric use—recurrence rates exceed 80% after cessation without immunomodulator bridge.
• If used: Low-dose prednisone 0.2–0.5 mg/kg/day × ≤2 weeks, tapered rapidly while escalating colchicine/IL-1 inhibitor.
• Ideal scenario: “Triple therapy” (NSAID + colchicine + short-course steroid) for induction only, not long-term maintenance.

Key Clinical Pearls & Emerging Trends

1. Biomarkers:
   • CRP >50 mg/L predicts recurrence risk (OR 2.7; Eur Heart J 2021). Serial CRP at diagnosis, week 2, and 4 months guides therapy duration.
   • Troponin elevation in 30–50% of cases (due to epicardial involvement); distinguish from MI by absence of dynamic changes + normal LV function on echo.
2. Imaging Advancements:
   • Cardiac MRI with late gadolinium enhancement (LGE) of pericardium predicts chronicity/recurrence.
   • Pericardial thickness >4 mm onecho suggests constrictive physiology—reassess at 3 months if symptoms persist.
3. Special Populations:
   • Pregnancy: NSAIDs contraindicated in 3rd trimester; use prednisone <20 mg/day or colchicine (Category B). IL-1 inhibitors considered only if life-threatening.
   • Post-cardiac injury syndrome (PCIS): Aspirin first-line; colchicine non-inferior to aspirin in POST trial (JAMA 2023).
4. Long-Term Outcomes:
   • Mortality <1% in idiopathic cases—but rises significantly with tuberculous, purulent, or malignant etiology.
   • Constriction develops in <5% of acute cases; screen if dyspnea/edema persist after inflammation resolves.

Summary of Evidence-Based Recommendations

Guideline Sources: ESC 2023 Pericardial Diseases Guideline, AHA Scientific Statement (Circulation 2022), ICE-Pericarditis Consensus (JACC 2021), Cochrane Review (2024 update).